Jazz Pharmaceuticals heads into its May 6 Q1 earnings report with short sellers meaningfully on the back foot after a sharp squeeze in late April.
The short interest story has been the defining positioning move of the past two weeks. Short interest peaked at around 12% of the free float in mid-to-late April, then dropped sharply on April 23-24 — falling to roughly 9% of the float, where it has since stabilised. That's a decline of about 3 percentage points in a matter of days, equivalent to over 1.7 million shares covered. Cost to borrow has fallen in lockstep, dropping 39% over the past week to a very modest 0.24%, confirming that the borrow market is not under stress. Availability remains ample, with no sign of a tightening lending pool heading into the print.
Options traders are far more relaxed than short sellers were a month ago. The put/call ratio has drifted to 0.51, slightly below its 20-day average of 0.56 — a tilt toward call activity rather than defensive hedging. That's a notable contrast to the elevated PCR readings seen in early April (above 0.80), when the same stock was attracting materially more downside protection. The shift aligns with a stock up 13.5% on the month, closing at $212.26, and up 4.1% on the week.
The analyst community has been broadly constructive. Most recent moves lifted price targets: Leerink and Barclays both raised targets to $225 ahead of the print, while B of A Securities and Wells Fargo carry the most optimistic targets in the $250-275 range. The mean consensus target is $230, implying around 8% upside from current levels. Bulls point to the portfolio diversification strategy — particularly the Epidiolex franchise and the oncology asset Ziihera — as drivers of durable revenue growth beyond the narcolepsy business. Bears counter that competition in the narcolepsy space is intensifying and that Ziihera, while showing positive clinical data, faces meaningful commercial risk with a 2030 revenue projection of just over $1 billion. The factor scores add nuance: the analyst recommendation differential ranks in the 92nd percentile, suggesting consensus is more positive on Jazz than on most pharma peers, but EPS surprise history is weaker, sitting in just the 22nd percentile.
One institutional flow stands out. Franklin Resources added approximately 1.1 million shares as of April 1 — a material increase, bringing its total position to nearly 1.8 million shares, or roughly 2.9% of the company. That represents one of the largest single-holder additions in the recent data and suggests at least one active manager took conviction ahead of the quarter.
The Q1 print arrives with sentiment having swung from cautious to constructive in the space of a month — the key test is whether the underlying revenue and pipeline data can justify the short squeeze and the re-rating.
See the live data behind this article on ORTEX.
Open JAZZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
